mtDNA mutations in invasive cervix tumors: A retrospective analysis

Cancer Letters

Volumn 243, Issue 2, 2006, Pages 193-201

  Allalunis Turner, Joan ^a,b   Ma, Ivy ^b   Hanson, John ^b   Pearcey, Robert G ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Cervix cancer; Mitochondrial genome; mtDNA mutations; Predictive markers

Indexed keywords

CISPLATIN; MITOCHONDRIAL DNA;

ADULT; AGED; ARTICLE; AUTOMATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE CERVIX TUMOR;

ADULT; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX I; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 33749266199     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.035     Document Type: Article

References (53)

1. Franco E.L., Schlecht N.F., and Saslow D. The epidemiology of cervical cancer. Cancer J. 9 (2003) 348-359
2. Grogan M., Thomas G.M., Melamed I., Wong F.L., Pearcey R.G., Joseph P.K., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
3. Perez C.A., Grigsby P.W., Nene S.M., Camel H.M., Galakatos A., Kao M.S., et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 69 (1992) 2796-2806
4. Alvarez R.D., Soong S.J., Kinney W.K., Reid G.C., Schray M.F., Podratz K.C., et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol. Oncol. 35 (1989) 130-135
5. Obermair A., Wanner C., Bilgi S., Speiser P., Kaider A., Reinthaller A., et al. Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. Am. J. Obstet. Gynecol. 178 (1998) 314-319
6. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., and West C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br. J. Cancer 83 (2000) 620-625
7. Knocke T.H., Weitmann H.D., Feldmann H.J., Selzer E., and Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 53 (1999) 99-104
8. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48 (1998) 149-156
9. Hockel M., Schlenger K., Mitze M., Schaffer U., and Vaupel P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6 (1996) 3-9
10. Rofstad E.K., Sundfor K., Lyng H., and Trope C.G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 83 (2000) 354-359
11. Kainz C., Kohlberger P., Gitsch G., Sliutz G., Breitenecker G., and Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol. Oncol. 57 (1995) 212-214
12. Ebara T., Mitsuhashi N., Saito Y., Sakurai H., Hasegawa M., Takahashi M., et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol. Oncol. 63 (1996) 216-218
13. Skomedal H., Kristensen G.B., Lie A.K., and Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol. 73 (1999) 223-228
14. Shiohara S., Shiozawa T., Miyamoto T., Feng Y.Z., Kashima H., Kurai M., et al. Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch. 446 (2005) 626-633
15. Sanseverino F., Torricelli M., Petraglia F., and Giordano A. Role of the retinoblastoma family in gynecological cancer. Cancer Biol. Ther. 2 (2003) 636-641
16. Graflund M., Sorbe B., Sigurdardottir S., and Karlsson M.G. Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2/neu and DNA ploidy in early cervical carcinoma: correlation with clinical outcome. Oncol. Rep. 12 (2004) 169-176
17. Dellas A., Schultheiss E., Leivas M.R., Moch H., and Torhorst J. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. Anticancer Res. 18 (1998) 3991-3998
18. Kirches E., Krause G., Warich-Kirches M., Weis S., Schneider T., Meyer-Puttlitz B., et al. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int. J. Cancer 93 (2001) 534-538
19. Fliss M.S., Usadel H., Caballero O.L., Wu L., Buta M.R., Eleff S.M., et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287 (2000) 2017-2019
20. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 20 (1998) 291-293
21. Parrella P., Seripa D., Matera M.G., Rabitti C., Rinaldi M., Mazzarelli P., et al. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett. 190 (2003) 73-77
22. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 (1999) 1482-1488
23. van den Heuvel L., and Smeitink J. The oxidative phosphorylation (OXPHOS) system: nuclear genes and human genetic diseases. Bioessays 23 (2001) 518-525
24. Schon E.A. Mitochondrial genetics and disease. Trends Biochem. Sci. 25 (2000) 555-560
25. Chomyn A. Mitochondrial genetic control of assembly and function of complex I in mammalian cells. J. Bioenerg. Biomembr. 33 (2001) 251-257
26. Parrella P., Xiao Y., Fliss M., Sanchez-Cespedes M., Mazzarelli P., Rinaldi M., et al. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 61 (2001) 7623-7626
27. Sanchez-Cespedes M., Parrella P., Nomoto S., Cohen D., Xiao Y., Esteller M., et al. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res. 61 (2001) 7015-7019
28. Yeh J.J., Lunetta K.L., van Orsouw N.J., Moore F.D.J., Mutter G.L., Vijg J., et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19 (2000) 2060-2066
29. Coller H.A., Khrapko K., Bodyak N.D., Nekhaeva E., Herrero-Jimenez P., and Thilly W.G. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat. Genet. 28 (2001) 147-150
30. Allalunis-Turner M.J., Pearcey R.G., Barron G.M., Buryn D.A., Babiak J.C., and Honore L.H. Inherent radiosensitivity testing of tumor biopsies obtained from patients with carcinoma of the cervix or endometrium. Radiother. Oncol. 22 (1991) 201-205
31. Brandon M.C., Lott M.T., Nguyen K.C., Spolim S., Navathe S.B., Baldi P., and Wallace D.C. MITOMAP: a human mitochondrial genome database-2004 update. Nucleic Acids Res. 33 Database Issue (2005) D611-D613
32. Taylor R.W., Taylor G.A., Durham S.E., and Turnbull D.M. The determination of complete human mitochondrial DNA sequences in single cells: implications for the study of somatic mitochondrial DNA point mutations. Nucleic Acids Res. 29 (2001) E74
33. Brown M.D., Voljavec A.S., Lott M.T., Torroni A., Yang C.C., and Wallace D.C. Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics 130 (1992) 163-173
34. Howell N., Kubacka I., Halvorson S., Howell B., McCullough D.A., and Mackey D. Phylogenetic analysis of the mitochondrial genomes from Leber hereditary optic neuropathy pedigrees. Genetics 140 (1995) 285-302
35. Kosel S., Grasbon-Frodl E.M., Mautsch U., Egensperger R., von Eitzen U., Frishman D., et al. Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. Neurogenetics 1 (1998) 197-204
36. Tan D.J., Bai R.K., and Wong L.J. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 62 (2002) 972-976
37. Matsuyama W., Nakagawa M., Wakimoto J., Hirotsu Y., Kawabata M., and Osame M. Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer. Hum. Mutat. 21 (2003) 441-443
38. Carew J.S., Zhou Y., Albitar M., Carew J.D., Keating M.J., and Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17 (2003) 1437-1447
39. Zhu W., Qin W., Bradley P., Wessel A., Puckett C.L., and Sauter E.R. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis 26 (2005) 145-152
40. Liu V.W., Shi H.H., Cheung A.N., Chiu P.M., Leung T.W., Nagley P., et al. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 61 (2001) 5998-6001
41. Chen J.Z., Gokden N., Greene G.F., Green B., and Kadlubar F.F. Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hyper-mutagenesis. Carcinogenesis 24 (2003) 1481-1487
42. Knight J.C. Regulatory polymorphisms underlying complex disease traits. J. Mol. Med. 83 (2005) 97-109
43. Chomyn A. Mitochondrial genetic control of assembly and function of complex I in mammalian cells. J. Bioenerg. Biomembr. 33 (2001) 251-257
44. Bai Y., Hu P., Park J.S., Deng J.H., Song X., Chomyn A., et al. Genetic and functional analysis of mitochondrial DNA-encoded complex I genes. Ann. NY Acad. Sci. 1011 (2004) 272-283
45. Grossman L.I., and Shoubridge E.A. Mitochondrial genetics and human disease. Bioessays 18 (1996) 983-991
46. Singh K.K. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann. NY Acad. Sci. 1019 (2004) 260-264
47. Dufour E., and Larsson N.G. Understanding aging: revealing order out of chaos. Biochim. Biophys. Acta 1658 (2004) 122-132
48. Bush R.S., Jenkin R.D., Allt W.E., Beale F.A., Bean H., Dembo A.J., et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer Suppl. 37 (1978) 302-306
49. Grogan M., Thomas G.M., Melamed I., Wong F.L., Pearcey R.G., Joseph P.K., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
50. Wilailak S., Rochanawutanon M., Srisupundit S., Aumkhyan A., and Pattanapanyasat K. Flow cytometric analysis of DNA ploidy and S-phase fraction of Stage IIIB cervical carcinoma. Eur. J. Gynaecol. Oncol. 25 (2004) 428-430
51. Gasinska A., Urbanski K., Jakubowicz J., Klimek M., Biesaga B., and Wilson G.D. Tumour cell kinetics as a prognostic factor in squamous cell carcinoma of the cervix treated with radiotherapy. Radiother. Oncol. 50 (1999) 77-84
52. Kristensen G.B., Kaern J., Abeler V.M., Hagmar B., Trope C.G., and Pettersen E.O. No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients. Gynecol. Oncol. 57 (1995) 79-85
53. Lewis P.D., and Parry J.M. In silico p53 mutation hotspots in lung cancer. Carcinogenesis 25 (2004) 1099-1107